James E Flynn
CIK 1352546 · last filed 2024-06-14
James E Flynn is a corporate insider who has filed 58 SEC Form 4 insider transactions across 34 companies since 2007. The most recent filing, for NUVL, was dated Jun 14, 2024. Across all open-market trades the lifetime net is +$143.0M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $288.0M across reported positions. 442 SEC filings were submitted jointly with DEERFIELD MANAGEMENT COMPANY, L.P.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$288.03M
Companies
34
Total Filings
58
Lifetime Open-Market Net
$142.97M
Filer Profile
Reported Address
780 THIRD AVENUE37TH FLOOR
NEW YORK, NY 10017
Related Filers
DEERFIELD MANAGEMENT COMPANY, L.P. — 442 joint filings, latest 2026-07-17
Deerfield Mgmt L.P. — 382 joint filings, latest 2026-07-17
Deerfield Special Situations Fund, L.P. — 278 joint filings, latest 2021-07-13
DEERFIELD PARTNERS, L.P. — 196 joint filings, latest 2026-07-17
Deerfield Special Situations Fund International LTD — 142 joint filings, latest 2013-07-18
Deerfield Mgmt III, L.P. — 82 joint filings, latest 2026-06-11
Deerfield Private Design Fund III, L.P. — 82 joint filings, latest 2026-06-11
DEERFIELD INTERNATIONAL LTD — 63 joint filings, latest 2011-06-07
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Nuvalent, Inc. (NUVL) Delisted | Director | 2,499 | $123.96 | $309.8K | $0 | 2 | 2024-06-14 |
| CareMax, Inc. (CMAXW) Delisted | Director | 15,811,090 | $0.01 | $151.8K | $0 | 1 | 2023-11-21 |
| Oncorus, Inc. (ONCR) Delisted | Director | 1,218,135 | $0.12 | $146.8K | $164.89M | 3 | 2022-12-30 |
| Acutus Medical, Inc. (AFIB) Delisted | Director | — | $0.09 | — | $0 | 1 | 2022-07-05 |
| DA32 Life Science Tech Acquisition Corp. (DALS) Delisted | Director | — | $10.32 | — | $0 | 1 | 2021-08-09 |
| MIRM | 10%+ Owner | 99,325 | $89.32 | $8.87M | -$8.69M | 1 | 2021-07-07 |
| LRMR | Director | 1,943,423 | $3.87 | $7.51M | $48.00M | 1 | 2021-07-02 |
| EWTX | 10%+ Owner | 1,572,960 | $41.05 | $64.57M | $40.00M | 1 | 2021-03-30 |
| LUMOS PHARMA, INC. (LUMO) Delisted | 10%+ Owner | 907,252 | $4.34 | $3.94M | -$13.70M | 1 | 2021-01-08 |
| CalciMedica, Inc. (GRAY) Delisted | 10%+ Owner | 132,426 | $5.50 | $728.3K | $200.00M | 1 | 2020-10-01 |
| RVMD | 10%+ Owner | 798,795 | $190.74 | $152.36M | $61.20M | 1 | 2020-02-18 |
| FIXX | Director | 0 | $12.57 | $0 | -$64.13M | 2 | 2020-01-31 |
| AdaptHealth Corp. (AHCOW) Delisted | Director | 20,000 | — | — | $0 | 1 | 2019-11-13 |
| ACRS | 10%+ Owner | 1,166,959 | $5.26 | $6.14M | -$18.83M | 1 | 2019-05-13 |
| XERS | 10%+ Owner | 878,518 | $8.66 | $7.61M | -$638.7K | 1 | 2019-01-30 |
| PRTO | Director | 3,742 | $27.55 | $103.1K | $0 | 2 | 2017-12-04 |
| Societal CDMO, Inc. (REPH) Delisted | 10%+ Owner | 407,450 | $2.09 | $851.6K | -$4.24M | 1 | 2017-06-14 |
| EHTH | 10%+ Owner | 1,062,874 | $0.84 | $897.1K | -$7.70M | 2 | 2016-06-02 |
| Larimar Therapeutics, Inc. (ZFGN) Delisted | 10%+ Owner | 46,777 | — | — | $12.08M | 2 | 2016-02-17 |
| AveXis, Inc. (AVXS) Delisted | Director | — | — | — | $0 | 1 | 2016-02-12 |
| ALIMERA SCIENCES INC (ALIM) Delisted | 10%+ Owner | 308,286 | $5.54 | $1.71M | $7.26M | 2 | 2015-12-03 |
| ANTARES PHARMA, INC. (ATRS) Delisted | 10%+ Owner | 3,388,846 | $5.59 | $18.94M | -$16.10M | 3 | 2015-07-17 |
| CAS MEDICAL SYSTEMS INC (CASM) Delisted | 10%+ Owner | 3,200,000 | — | — | $0 | 1 | 2015-01-05 |
| Dicerna Pharmaceuticals Inc (DRNA) Delisted | 10%+ Owner | 825,603 | $38.22 | $31.55M | $91.43M | 2 | 2014-11-10 |
| ISTA PHARMACEUTICALS INC (ISTA) Delisted | 10%+ Owner | 766,135 | — | — | -$162.52M | 2 | 2011-05-06 |
| MEDICINES CO /DE (MDCO) Delisted | 10%+ Owner | 2,536,035 | — | — | -$22.91M | 1 | 2011-04-01 |
| DUSA | 10%+ Owner | 719,295 | $55.57 | $39.97M | -$21.01M | 1 | 2011-03-17 |
| NeuroMetrix, Inc. (NURO) Delisted | 10%+ Owner | 9 | $4.58 | $41 | $24.64M | 2 | 2010-12-14 |
| HI TECH PHARMACAL CO INC (HITK) Delisted | 10%+ Owner | 210,662 | — | — | -$28.93M | 1 | 2010-12-13 |
| PAR PHARMACEUTICAL COMPANIES, INC. (PRX) Delisted | 10%+ Owner | 1,370,787 | — | — | -$131.60M | 2 | 2009-08-19 |
| EMAGEON INC (EMAG) Delisted | 10%+ Owner | 1,173,658 | $20.38 | $23.91M | -$5.37M | 1 | 2009-03-02 |
| Bio Green Med Solution, Inc. (CYCCP) Delisted | 10%+ Owner | 663,816 | $5.05 | $3.35M | -$730.4K | 1 | 2008-11-14 |
| NITROMED INC (NTMD) Delisted | 10%+ Owner | 1,908,740 | — | — | $1.62M | 4 | 2008-07-25 |
| VIA Pharmaceuticals, Inc. (VIAP) Delisted | 10%+ Owner | 748,013 | — | — | -$1.06M | 3 | 2007-11-07 |
Recent Filings
58 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-14 | Nuvalent, Inc. (NUVL) Delisted | Grant (A) | +9,996 | $0 | EDGAR |
| 2023-11-21 | CareMax, Inc. (CMAXW) Delisted | Exer (M) | +24,246 | $0 | EDGAR |
| 2022-12-30 | Oncorus, Inc. (ONCR) Delisted | Sell (S) | −2,689,880 | -$706.0K | EDGAR |
| 2022-07-05 | Acutus Medical, Inc. (AFIB) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-08-09 | DA32 Life Science Tech Acquisition Corp. (DALS) Delisted | Disp (D) | — | $0 | EDGAR |
| 2021-07-30 | Nuvalent, Inc. (NUVL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-07-07 | MIRM | Sell (S) | −533,400 | -$8.69M | EDGAR |
| 2021-07-02 | LRMR | Buy (P) | +5,485,680 | $48.00M | EDGAR |
| 2021-03-30 | EWTX | Mixed | +15,732,548 | $40.00M | EDGAR |
| 2021-02-18 | Oncorus, Inc. (ONCR) Delisted | Buy (P) | +2,400,000 | $45.60M | EDGAR |
Showing 1–10 of 58
Page 1 of 6
Next
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.